Novavax Stock is Slipping
The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...
The US Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug (IND) application for ...
(Reuters) -Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ...
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Novavax. This level of activity is out of the ordinary.
In addition, Novavax is eligible to receive tiered royalties on net sales from COVID-19 standalone and COVID-19 combination products. This enables Novavax's meaningful participation in future ...
Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...
Indian retailer Nykaa reported a 72% rise in its second-quarter profit on Tuesday as its mainstay beauty products segment ...
Novavax also announced another, unnamed, large pharma company has also signed a deal to license the adjuvant for use in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback